Cite
HARVARD Citation
Hexner, E. et al. (n.d.). Open‐label study of oral CEP‐701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2‐V617F mutation. British journal of haematology. pp. 83-93. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Hexner, E. et al. (n.d.). Open‐label study of oral CEP‐701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2‐V617F mutation. British journal of haematology. pp. 83-93. [Online].